within Pharmacolibrary.Drugs.ATC.P;

model P02BA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 6.766666666666666e-07,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0014,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005166666666666667,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>P02BA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Oxamniquine is an anthelmintic medication primarily used for the treatment of schistosomiasis, specifically infections caused by Schistosoma mansoni. Its use has significantly declined due to the widespread adoption of praziquantel, but oxamniquine remains in use in some regions. It is not widely used in most countries today, having largely been replaced by other agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults after a single oral dose.</p><h4>References</h4><ol><li><p>Daneshmend, TK, &amp; Homeida, MA (1987). Oxamniquine pharmacokinetics in hepatosplenic schistosomiasis in the Sudan. <i>The Journal of antimicrobial chemotherapy</i> 19(1) 87–93. DOI:<a href=\"https://doi.org/10.1093/jac/19.1.87\">10.1093/jac/19.1.87</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3104279/\">https://pubmed.ncbi.nlm.nih.gov/3104279</a></p></li><li><p>Wilby, KJ, et al., &amp; Ensom, MH (2013). A review of the pharmacokinetic implications of schistosomiasis. <i>Clinical pharmacokinetics</i> 52(8) 647–656. DOI:<a href=\"https://doi.org/10.1007/s40262-013-0055-8\">10.1007/s40262-013-0055-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23479397/\">https://pubmed.ncbi.nlm.nih.gov/23479397</a></p></li><li><p>Alwan, SN, et al., &amp; LoVerde, PT (2023). Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis. <i>PLoS pathogens</i> 19(7) e1011018–None. DOI:<a href=\"https://doi.org/10.1371/journal.ppat.1011018\">10.1371/journal.ppat.1011018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37428793/\">https://pubmed.ncbi.nlm.nih.gov/37428793</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end P02BA02;
